Pharsight

Symtuza patents expiration

SYMTUZA's oppositions filed in EPO
SYMTUZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6703396 JANSSEN PRODS Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(3 months ago)

US7390791 JANSSEN PRODS Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(10 months from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(2 years from now)

US8148374 JANSSEN PRODS Modulators of pharmacokinetic properties of therapeutics
Sep, 2029

(5 years from now)

US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8597876 JANSSEN PRODS Method of treating HIV infection
Jun, 2019

(4 years ago)

US7470506 JANSSEN PRODS Fitness assay and associated methods
Jun, 2019

(4 years ago)

US9889115 JANSSEN PRODS Fitness assay and associated methods
Jun, 2019

(4 years ago)

US6642245 JANSSEN PRODS Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US7803788 JANSSEN PRODS Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(2 years ago)

US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(8 years from now)

US10786518 JANSSEN PRODS Compositions and methods of treating HIV
Jul, 2038

(14 years from now)

Symtuza is owned by Janssen Prods.

Symtuza contains Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate.

Symtuza has a total of 14 drug patents out of which 7 drug patents have expired.

Expired drug patents of Symtuza are:

  • US8597876
  • US7470506
  • US9889115
  • US6642245
  • US7803788
  • US6703396
  • US8518987

Symtuza was authorised for market use on 17 July, 2018.

Symtuza is available in tablet;oral dosage forms.

Symtuza can be used as treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase in adults who are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-associated substitutions.

Drug patent challenges can be filed against Symtuza from 06 November, 2019.

The generics of Symtuza are possible to be released after 19 July, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Combination(NC) Jul 17, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage

SYMTUZA family patents

Family Patents